Core Viewpoint - Beijing Jiukang Biotechnology Co., Ltd. announces the suspension of the conversion of its convertible bonds "Jiukang Convertible Bonds" (bond code: 123150) during the rights distribution period from August 28, 2025, to September 4, 2025, and will resume conversion on September 5, 2025 [1] Summary by Relevant Sections - The company guarantees the authenticity, accuracy, and completeness of the information disclosed, ensuring no false records, misleading statements, or significant omissions [1] - The suspension of the bond conversion is in accordance with the regulations outlined in the prospectus for the issuance of convertible bonds to unspecified objects [1] - Bondholders are advised to pay attention to the resumption of conversion on the first trading day after the rights distribution registration date [1]

| 证券代码：300406 | 证券简称：九强生物 | 公告编号：2025-071 | | --- | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | | 北京九强生物技术股份有限公司 关于九强转债恢复转股的提示性公告 特此公告。 北京九强生物技术股份有限公司董事会 2025 年 9 月 4 日 1、债券代码：123150 ；债券简称：九强转债 2、恢复转股时间：自 2025 年 9 月 5 日起恢复转股 北京九强生物技术股份有限公司（以下简称"公司"）因实施 2025 年半年度权益 分派，根据《北京九强生物技术股份有限公司创业板向不特定对象发行可转换公司债 券募集说明书》及相关规定，公司可转换公司债券（债券代码：123150 ；债券简称： 九强转债 ）自 2025 年 8 月 28 日至本次权益分派股权登记日（2025 年 9 月 4 日）止暂 停转股。具体内容详见公司于 2025 年 8 月 27 日披露的《关于实施权益分派期间九强 转债暂停转股的提示性公告》（公告编号：2025-065）。 根据规定，"九强转债" 将于本次权益分派股权登记日后的第一个交易日即 2025 年 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

人民财讯9月3日电，九强生物（300406）9月3日晚间公告，公司近日收到北京市药监局颁发的《医疗器 械注册证》，产品名称为肝素结合蛋白测定试剂盒(胶乳免疫比浊法)，该试剂盒用于体外定量测定人血 浆中肝素结合蛋白(HBP)的含量。 ...

Core Viewpoint - The company has received a medical device registration certificate for its Heparin Binding Protein (HBP) assay kit, which is expected to enhance its product portfolio and core competitiveness, although it will not have a significant impact on recent operations and performance [1]. Group 1 - The product is a Heparin Binding Protein assay kit using the latex immunoturbidimetric method [1]. - The registration certificate was issued by the Beijing Drug Administration, with the registration number 京械注准20252400796 [1]. - The registration falls under Class II medical devices and is valid until August 31, 2030 [1]. Group 2 - The acquisition of this registration certificate enriches the company's product categories [1]. - It is expected to have a positive impact on the company's future development [1]. - However, it is noted that there will be no major impact on the company's recent operations and performance [1].

| 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 肝素结合蛋白测定 试剂盒（胶乳免疫比 | 京 械 注 准 20252400796 | Ⅱ | 自批准之日起有效期 至 2030 年 08 月 31 日 | 本试剂盒用于体外定量 测定人血浆中肝素结合 | | | 浊法） | | | | 蛋白（HBP）的含量。 | 上述产品医疗器械注册证的取得，丰富了公司产品类别，有利于增强公 司的核心竞争力，对公司未来发展具有正面影响，但对近期的生产经营和业 绩不会产生重大影响，敬请投资者注意风险。 特此公告。 北京九强生物技术股份有限公司 董事会 北京九强生物技术股份有限公司 关于取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 证券代码：300406 | 证券简称：九强生物 公告编号：2025-0 ...

Group 1 - Huazhong Securities has been approved to issue subordinate corporate bonds with a total face value of no more than 10 billion yuan [1] - Jinbei Automotive plans to invest 240 million yuan to establish an automotive industry investment fund focusing on electrification, intelligence, and low carbon [1] - Linyang Energy is expected to win a bid for a 244 million yuan metering equipment project from Southern Power Grid [1][2] Group 2 - Renfu Pharmaceutical's subsidiary has received drug registration certificates for two products, including a medication for acute hypotension [3][4] - Nanjing Steel plans to distribute a cash dividend of 0.1186 yuan per share [5][6] - Pairui Co. has signed a strategic cooperation agreement with Xi'an Power Electronics Research Institute to develop power devices [7][8] Group 3 - Haixing Electric is expected to win a bid for a 214 million yuan metering equipment project from Southern Power Grid [9][10] - Kuangda Technology is planning a change in control, leading to a continued suspension of its stock [11][12] - Samsung Medical is expected to win a bid for a 274 million yuan metering equipment project from Southern Power Grid [13][14] Group 4 - Jiukang Bio has obtained a medical device registration certificate for a specific diagnostic kit [15][16] - Hechuan Technology's minority shareholder plans to transfer a 13% stake in a subsidiary [17][18] - DiAo Micro has launched a new eUSB2 repeater product for various electronic applications [19][20] Group 5 - David Medical's electric surgical table registration application has been accepted [21][22] - Hangxin Technology plans to apply for a total of 280 million yuan in bank credit [23][24] - Liyuan Technology's non-independent director has resigned [25][26] Group 6 - Ningbo Construction's subsidiary has won a construction project bid worth 729 million yuan [27][28] - Huaren Pharmaceutical's subsidiary has received approval for a raw material drug [29][30] - Suwen Electric plans to distribute a cash dividend of 1 yuan per 10 shares [31][32] Group 7 - Solar Energy has received 1.692 billion yuan in renewable energy subsidies [33][34] - Wangli Security has obtained a patent for a new lock structure [35][36] - Zhejiang Energy's vice chairman has resigned due to age reasons [37][38] Group 8 - Beilu Pharmaceutical's subsidiary has passed GMP certification in Brazil [39][40] - Zhejiang Communications has a subsidiary that is expected to win a highway project bid [41][42] - Xinzhi Group has received a government subsidy of 11.1978 million yuan [43][44] Group 9 - Dong'an Power's engine sales in August increased by 3.44% year-on-year [45][46] - Baiyun Mountain's subsidiary has passed the consistency evaluation for two generic drugs [47][48] - Yipin Hong's subsidiary has received a drug registration certificate for a specific injection [49][50] Group 10 - Far East Holdings' subsidiary has won multiple contracts totaling 1.689 billion yuan [51][52] - Good Housekeeping's shareholder plans to reduce holdings by up to 3.5 million shares [53][54] - Guanghong Technology's shareholders have set a transfer price of 23.33 yuan per share [55][56] Group 11 - Keli Sensor plans to acquire 45% of Huahong Technology's shares for 122 million yuan [57][58] - Jianmin Group's furosemide oral solution has been approved for market launch [59][60] - Jinghua Laser's directors plan to reduce their holdings by up to 143,420 shares [61][62] Group 12 - Zhuyue Group is planning a share transfer that will change its controlling shareholder [63][64] - Terid has pre-bid for two projects totaling approximately 698 million yuan [65][66] - Zhonghuan Hailu is planning a change in control, leading to a continued suspension of its stock and convertible bonds [67][68] Group 13 - Great Wall Motors reported August sales of 115,600 vehicles, a year-on-year increase of 22.33% [69][70] - Guizhou Tire's controlling shareholder has committed not to reduce holdings for 12 months [71][72] - San Da Membrane's shareholder plans to reduce holdings by up to 1% of the company's shares [73][74] Group 14 - Chint Electric has decided to terminate the spin-off of its subsidiary for listing [75][76] - Jusaylong's shareholder plans to reduce holdings by up to 1% of the company's shares [77][78]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月2日，九强生物发布公告称，公司胃泌素17测定试剂盒 （胶乳免疫比浊法）获得北京市药品监督管理局颁发的医疗器械注册证，有效期至2030年8月31日。公 告显示，该试剂盒用于体外定量测定人血清中胃泌素17（G—17）的含量。 ...

人民财讯9月2日电，九强生物(300406)9月2日晚间公告，公司近日收到北京市药监局颁发的《医疗器械 注册证》，产品名称为胃泌素17测定试剂盒（胶乳免疫比浊法），该试剂盒用于体外定量测定人血清中 胃泌素17（G-17）的含量。 转自：证券时报 ...

智通财经APP讯，九强生物(300406.SZ)发布公告，公司于近日收到北京市药品监督管理局颁发的《医疗 器械注册证》，产品名称：胃泌素17测定试剂盒(胶乳免疫比浊法)。该试剂盒用于体外定量测定人血清 中胃泌素17(G-17)的含量。 ...